180 Life Sciences Corp. — Q1 2023 Form 10-Q
Reporting period: Three months ended March 31, 2023. The filing identifies the registrant as 180 Life Sciences Corp. (NASDAQ: ATNF; warrants: ATNFW), a clinical-stage biotechnology company developing therapies for chronic pain, inflammation, fibrosis and related conditions. It reports no revenue.
Financial performance and position
- Revenue and margins: No revenue was generated. Operating loss was $4.80 million; margins are not meaningful for this pre-revenue business.
- Expenses and earnings: Operating expenses rose 30% to $4.80 million from $3.68 million. R&D was $795,000, including related-party costs, versus $707,000; G&A was $4.01 million versus $2.97 million. Net loss was $4.76 million ($1.27 per share), compared with net income of $1.56 million ($0.92 per share) in Q1 2022.
- Cash flow: Operating cash use was $3.87 million, up from $2.07 million. Financing cash use was $470,000, primarily loan repayments. Cash declined by $4.32 million to $2.65 million.
- Liquidity: Working capital shifted to a $926,000 deficit from $3.27 million of positive working capital at December 31, 2022. Management reported a minimum monthly cash requirement of approximately $900,000.
- Debt and liabilities: Loans payable totaled $871,000, of which $842,000 was current. Total liabilities were $7.78 million. Accrued expenses included a $765,000 litigation accrual.
- Other balance-sheet items: Total assets were $14.92 million, including $9.06 million of in-process R&D; stockholders’ equity was $7.14 million. Accumulated deficit was $112.17 million.
Material changes versus Q1 2022
- Results swung from $1.56 million net income to a $4.76 million net loss. The prior-year result included $5.23 million of non-cash income from changes in derivative fair value; that gain was only $53,000 in Q1 2023.
- G&A increased $1.04 million, mainly from higher professional fees and salaries, partly offset by lower insurance expense. R&D excluding related-party costs decreased $81,000, while related-party R&D rose $169,000.
- Operating cash use increased $1.80 million. Cash fell from $6.97 million at year-end 2022 to $2.65 million at quarter-end.
Outlook, risks and unusual items
- Going concern: The filing states that substantial doubt exists about the Company’s ability to continue as a going concern within one year after issuance. Management said subsequent financing and cash on hand were expected to support operations through May 2024; this is not assurance of funding or profitability.
- Subsequent financing: An offering closed April 10, 2023, raising approximately $3.0 million gross through common shares and warrants. All 1,170,860 pre-funded warrants were subsequently exercised for $117; none of the 1,570,680 common warrants had been exercised as of the filing. The offering and potential warrant exercises may dilute shareholders. The Company also repriced and extended certain existing warrants.
- Cash needs: Management estimated known contractual and other cash requirements of approximately $7.5 million for the remainder of 2023 and $27 million for 2024–2027. It expects continued losses and says additional financing will be needed; no credit facility or committed capital source was reported.
- Development risks: Product candidates remain in clinical or preclinical development. Trial outcomes, regulatory approval, commercialization, costs and timing are uncertain; the filing anticipates increased R&D and G&A spending.
- Litigation and insurance: The Company and its former executives are involved in multiple legal proceedings, including claims against former parties and disputes over advancement of legal fees and D&O insurance coverage. Outcomes and recoveries are uncertain. The filing describes favorable partial court rulings in the insurance dispute and an affirmed ruling in the Tyche matter, but neither establishes final recovery.
- Accounting and controls: The Company recorded a $3.34 million impairment of in-process R&D in Q4 2022; the remaining $9.06 million asset was assessed as not impaired at March 31, 2023. Management said disclosure controls were ineffective and a material weakness related to review precision for warrant fair value and in-process R&D valuation remained unremediated.
- Other unusual items: Q1 2023 included $557,000 of stock-based compensation. The Company reported a 1-for-20 reverse stock split effective December 19, 2022; financial statements reflect it retrospectively.
Key facts for investors to verify
- Whether the Company secures additional capital, its terms and the resulting dilution; compare actual cash use with management’s stated monthly cash requirement and runway estimate.
- Clinical and regulatory progress, trial costs and any changes to the development pipeline or in-process R&D valuation.
- Developments and potential cash exposure in the litigation matters, including D&O insurance coverage and the recorded litigation accrual.
- Remediation of the disclosed material weakness and effectiveness of financial reporting controls.
- Share-count and dilution disclosures: the balance sheet lists 3,746,906 common shares at March 31, while the equity roll-forward lists 3,706,469; the cover reports 5,317,586 shares outstanding as of May 15. Reconcile these figures with subsequent issuances and warrant activity.